Printer Friendly

Capio and Doctrin partner to develop AI together with KTH Royal Institute of Technology and Lund University.

M2 PHARMA-June 9, 2017-Capio and Doctrin partner to develop AI together with KTH Royal Institute of Technology and Lund University

(C)2017 M2 COMMUNICATIONS

Healthcare provider Capio AB (STO:CAPIO) announced on Thursday that along with Doctrin, it is taking the next step in a joint ambition to create the future of healthcare.

Under this partnership, along with KTH Royal Institute of Technology and Lund University, Capio and Doctrin are developing AI decision support tools helping healthcare professionals to prioritise, diagnose and treat patients.

Doctrin develops digital tools to support healthcare providers and has already developed a system that allows for the patient to summarise his or her own medical history. The patient answers questions about his or her symptoms on a smartphone or computer, which helps healthcare providers to deliver the appropriate care. This tool has been developed together with Capio.

As a next step, Doctrin and Capio now will jointly develop a decision support tool based on artificial intelligence (AI). Based on the medical history of the patient, along with medical guidelines, the tool will make suggestions to the healthcare professional on how to prioritize, diagnose and treat the patient.

Reportedly, the purpose is to support healthcare professionals to improve quality and ensure all patients receive the right care, at the right care level at the right time.

This tool is developed together with KTH Royal Institute of Technology, providing expertise in AI and machine learning, as well as with the Medical Faculty at Lund University conducting the scientific evaluation of the tool. Vinnova, Sweden's innovation agency is co-funding the development with a contribution of SEK1.9m.

Capio offers a broad range of high quality medical, surgical and psychiatric healthcare services through its hospitals, specialist clinics and primary care units.

(EUR1.00=SEK9.78)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 9, 2017
Words:307
Previous Article:Kleo Pharmaceuticals appoints Douglas J. Manion MD as CEO.
Next Article:Kissei Pharmaceutical and Vifor Fresenius Medical Care Renal Pharma sign agreement to market Avacopan in Japan.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters